news

CUPERTINO, Calif., March 14, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has signed an agreement with Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), that will give Endo the exclusive license to develop and commercialize DURECT’s sufentanil-containing transdermal patch in the U.S. and […]

CUPERTINO, Calif., Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Security Research Associates Spring Technology & Life Sciences Investor Conference at the Campton Place Hotel in San Francisco. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on

CUPERTINO, Calif., Feb. 16 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the initiation of the Phase II program for DURECT’s TRANSDUR(TM)-based sufentanil patch. Based on the results of our Phase I trial for our TRANSDUR-Sufentanil patch that showed good safety, tolerability and drug release for up to 7

CUPERTINO, Calif., Feb 10, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today its financial results for the three months and year ended December 31, 2004. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) Our net loss for the three months ended December 31, 2004 was $7.0 million or 13 cents per share, compared to a net loss

CUPERTINO, Calif., Feb. 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals systems company, today announced the completion of dosing of the Phase I pharmacokinetic study for DURECT’s TRANSDUR(TM)-based sufentanil patch. The Company also announced the completion of dosing of the first cohort of the on-going Phase II clinical study for DURECT’s SABER(TM)-based

CUPERTINO, Calif., and RALEIGH, N.C., Jan 28, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical systems company, and Voyager Pharmaceutical Corporation, a privately held specialty pharmaceutical company focused on diseases of aging, announced today the completion of enrollment for the recently approved study for the DURIN(TM)-based leuprolide acetate product candidate

CUPERTINO, Calif., Jan. 25 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Paula Mendenhall has joined DURECT as Senior Vice President of Operations. Dr. Mendenhall has over 30 years of pharmaceutical experience covering areas such as research, manufacturing and pharmaceutical operations. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “Dr. Mendenhall is a key addition to our management

CUPERTINO, Calif., Jan. 20 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter and year-end 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 10, 2005 at 4:30 p.m. EST with Jim Brown, President and Chief Executive

CUPERTINO, Calif., Jan. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced its intended clinical and corporate milestones for the fiscal year 2005. “These announced milestones are intended to assist the investment community to track our progress throughout the coming year,” said James E. Brown, President and CEO of DURECT. “DURECT will continue to drive

CUPERTINO, Calif., Jan. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the Company will host a reception to provide an update to its development pipeline and program objectives for fiscal year 2005. The presentation will be held at the Weinstein Gallery in San Francisco, CA. James E. Brown, President and Chief Executive Officer,